Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 6Neoplasms 5Colonic Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Ovarian Carcinosarcoma 1Neoplasms, Second Primary 1Locally Advanced Rectal Cancer (LARC) 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Paclitaxel 4pembrolizumab 3Cisplatin 3Doxorubicin 2Carboplatin 2Brachytherapy 2Biopsy 2trastuzumab deruxtecan 1sacituzumab govitecan 1relugolix 1dostarlimab 1dehydroftorafur 1belzutifan 1Watchful Waiting 1Vaginal Smears 1VMBP protocol 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Taxes 1Sutures 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Pregnancy Tests 1Practice Guidelines as Topic 1Platinum 1Papanicolaou Test 1Oxaliplatin 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Neoplasms × dostarlimab × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡